Cygnus Metals Launches Aggressive Exploration at Chibougamau Copper-Gold Project

Gartner Hosts 2026 Finance Symposium in Sydney

EXCLUSIVE-Activist Barington launches new proxy fight at Matthews, sources say

Australia's National Storage REIT agrees to $2.65 billion buyout by Brookfield–GIC consortium

BRIEF-Lilly's Jaypirca Met Primary Endpoint In Head-To-Head Phase 3 Study Versus Imbruvica

BRIEF-Regeneron Pharmaceuticals Says Lynozyfic Monotherapy In Newly Diagnosed Multiple Myeloma Shows Impressive Responses

Lynozyfic™ (Linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (Ndmm) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment

Notification of cessation of securities - NWS-NWSA.O

Regeneron Hosts Virtual Investor Event on Multiple Myeloma Program

Eli Lilly's Jaypirca Outperforms Imbruvica in Phase 3 CLL Trial

Lyell Immunopharma Reports High Response Rates for Ronde-Cel in Large B-Cell Lymphoma Trial

Lilly's Jaypirca (Pirtobrutinib) Met Its Primary Endpoint in First-of-Its-Kind, Head-to-Head Phase 3 Study Versus Imbruvica (Ibrutinib)

BNY Mellon Cuts Voting Power in Opthea to 6.37%

Wave Life Sciences Announces Interim Data from Phase 1 INLIGHT Trial of Obesity Drug WVE-007

Trump Administration Waives Biden-Era Fine Against Southwest Airlines -- Update

Pinglu's "Digital Farmer" Platform Solves Traditional Transaction Challenges